ArticleNature2022
Spatially resolved clonal copy number alterations in benign and malignant tissue.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers.
0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed
28.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
192 citing papers in PubMed, 300 citations in OpenAlex.
- A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.British journal of cancer · 2023Trial
- Decoding epithelial-mesenchymal transitions with multi-omics.Nature reviews. Genetics · 2026Review
- Gene expression profiles in benign prostate tissue reflect tumor proximity, grade, and molecular subtype.Journal of translational medicine · 2026Article
- IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.EMBO molecular medicine · 2026Article
- A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.Cancer discovery · 2026Article
- Computational approaches for multimodal lineage tracing.Nature reviews. Genetics · 2026Review
- Single-cell and spatial RNA sequencing in prostate cancer.Nature reviews. Urology · 2026Review
- Melanoma evolution in the lymph node shapes systemic outcomes.bioRxiv : the preprint server for biology · 2026Article
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Benchmarking copy number alteration inference methods for spatial transcriptomics.Nature communications · 2026Article
- Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis.Nature genetics · 2026Article
- Spatial Total RNA Sequencing of Formalin-Fixed Paraffin-Embedded Tissue by spRandom-seq.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Uncovering genes driving developmental stage progression in prostate cancer through spatial transcriptomics.Genes & diseases · 2026Article
- Spatial transcriptomics reveals clonal relationships between intraductal carcinoma and adjacent invasive prostate cancer.Histopathology · 2026Article
- DeepPathway: predicting pathway expression from histopathology images.Bioinformatics (Oxford, England) · 2026Article
- HisToSpatialCNV: an interpretable deep learning method predicting spatial copy number variations from histopathology images.Nature biomedical engineering · 2026Article
- Article
- Circulating tumour cells as a window into lethality in prostate cancer.Nature reviews. Urology · 2026Review
- Robust and generalizable CNV detection for single-cell sequencing assays.Nucleic acids research · 2026Article
- Advances in spatial omics for the analysis of prostate cancer.Analytical and bioanalytical chemistry · 2026Review
132 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors at 7 institutions in 4 countries.
Andrew Erickson *Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Mengxiao He *Department of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.ORCID http://orcid.org/0000-0001-5905-8467
Emelie Berglund *Department of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.
Maja MarklundDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.ORCID http://orcid.org/0000-0003-2627-2437
Reza MirzazadehDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.
Niklas SchultzScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
Linda KvastadDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.
Alma AnderssonDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.
Ludvig BergenstråhleDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.
Joseph BergenstråhleDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.ORCID http://orcid.org/0000-0002-1136-7719
Ludvig LarssonDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.ORCID http://orcid.org/0000-0003-4209-2911
Leire Alonso GaliciaDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.ORCID http://orcid.org/0000-0001-8437-1332
Alia ShamikhDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Elisa BasmaciDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Teresita Díaz De StåhlDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Timothy RajakumarNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Dimitrios DoultsinosNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0873-9873
Kim ThraneDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.
Andrew L JiProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-9688-5680
Paul A KhavariProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0098-4989
Firaz TarishScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
Anna TanoglidiDepartment of Clinical Pathology, University Uppsala Hospital, Uppsala, Sweden.
Jonas MaaskolaDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.ORCID http://orcid.org/0000-0002-6665-2664
Richard CollingNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-6344-9081
Tuomas MirttiDepartment of Pathology, University of Helsinki & Helsinki University Hospital, Helsinki, Finland.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Dan J WoodcockNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0576-044X
Thomas HelledayScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.ORCID http://orcid.org/0000-0002-7384-092X
Ian G MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5347-5083
Alastair D LambNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. alastair.lamb@nds.ox.ac.uk.
Joakim LundebergDepartment of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden. joakim.lundeberg@scilifelab.se.ORCID http://orcid.org/0000-0003-4313-1601
Science for Life Laboratory · SEUniversity of Oxford · GBKarolinska University Hospital · SEStanford University · USOpen Data Institute · GBUniversity of Helsinki · FIUppsala University Hospital · SE
Funding
Cancer Cell-Extrinsic and Intrinsic Regulators of TumorigenesisK08CA263187 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JI, ANDREW · 2021 to 2025
$1.1MCancer Research UK 25812NCI NIH HHS K08 CA263187Prostate Cancer UK PA14-022
Abstract
Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer
Indexed as
Clone CellsDNA Copy Number VariationsGenomic InstabilityNeoplasmsSpatial AnalysisEarly Detection of CancerGenome, HumanGenomicsHumansMaleModels, BiologicalProstateProstatic NeoplasmsTranscriptome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.